CMXC — Cell MedX Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Cell MedX, fiscal year end - May 31st, USD millions except per share, conversion factor applied.

	2020 May 31st	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0.096	0.007	0.006	0.003	0
Cost of Revenue
Gross Profit	0.086	0.004	0.004	0	0
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1.13	0.732	0.678	0.45	0.081
Operating Profit	-1.04	-0.725	-0.672	-0.448	-0.081
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.09	-0.911	-0.697	-0.495	-0.142
Net Income After Taxes	-1.09	-0.911	-0.697	-0.495	-0.142
Net Income Before Extraordinary Items
Net Income	-1.09	-0.911	-0.697	-0.495	-0.142
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1.09	-0.911	-0.697	-0.495	-0.142
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.022	-0.012	-0.011	-0.008	-0.002